We are live on ! Find out more
RXDX

Prometheus Biosciences, Inc. Common Stock
RXDX

Delisted

RXDX was delisted on the 15th of June, 2023.

Back to rankings

41 hedge funds and large institutions have $426M invested in Prometheus Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
41
Holders Change
+41
Holders Change %
–
% of All Funds
0.72%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
41
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$76.7M
2
PA
Perceptive Advisors
New York
+$68.4M
3
RI
RTW Investments
New York
+$67.4M
4
CA
CHI Advisors
New York
+$59.3M
5
CAM
Cormorant Asset Management
Massachusetts
+$43.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
MWNA
26
Marshall Wace North America
New York
$1.45M +$1.63M +79,171 New
Goldman Sachs
27
Goldman Sachs
New York
$1.08M +$1.22M +59,083 New
Citadel Advisors
28
Citadel Advisors
Florida
$1.02M +$1.16M +56,138 New
Alyeska Investment Group
29
Alyeska Investment Group
Illinois
$913K +$1.03M +50,000 New
LCM
30
Laurion Capital Management
New York
$913K +$1.03M +50,000 New
KCM
31
Kingdon Capital Management
New York
$730K +$826K +40,000 New
TD Asset Management
32
TD Asset Management
Ontario, Canada
$629K +$712K +34,465 New
PCM
33
Pinz Capital Management
New York
$572K +$646K +31,300 New
Geode Capital Management
34
Geode Capital Management
Massachusetts
$324K +$367K +17,772 New
CCM
35
CAAS Capital Management
New York
$274K +$310K +15,000 New
SCM
36
Silverarc Capital Management
Massachusetts
$274K +$310K +15,000 New
HP
37
Hound Partners
New York
$188K +$213K +10,292 New
MS
38
Maven Securities
Jersey
$152K +$172K +8,333 New
Bank of America
39
Bank of America
North Carolina
$22K +$25.4K +1,228 New
UBS Group
40
UBS Group
Switzerland
$14K +$16K +776 New
Morgan Stanley
41
Morgan Stanley
New York
$5K +$5.97K +289 New
1
2

RXDX Hedge Fund Activity: Q1 2021 in Review

41 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q1 2021, worth a combined $426M.

Buyers outnumbered sellers: 41 funds opened new RXDX positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Eventide Asset Management, opening a new position worth an estimated $76.7M.

  • 41 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $426M of Prometheus Biosciences, Inc. Common Stock stock for Q1 2021.
  • 41 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +41 holders.
  • The largest Prometheus Biosciences, Inc. Common Stock buyer in Q1 2021 was Eventide Asset Management, an estimated $76.7M added.

Based on aggregated 13F filings for Q1 2021.